TRAP1 regulates complement activation and mitochondrial stress adaptation to promote tumor cell resistance to complement-dependent cytotoxicity
The mitochondrial chaperone TRAP1 promotes tumor cell resistance to complement-dependent cytotoxicity by recruiting Factor H to inhibit C3b deposition, directly blocking C9 polymerization to prevent membrane attack complex assembly, and mitigating intracellular mitochondrial stress, thereby identifying it as a promising therapeutic target to enhance antibody-based cancer immunotherapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer cells are masters of survival. When the body's immune system sends out specialized antibodies to mark a tumor for destruction, the cancer often finds a way to shrug off the attack. One of the immune system's most powerful weapons is a process called complement-dependent cytotoxicity. Imagine the immune system as a team of soldiers that, once they have tagged a target, call in a heavy artillery unit. This unit assembles a complex structure on the surface of the cancer cell, punching a hole in its outer wall and causing the cell to burst. However, many tumors have developed shields to block this artillery fire, making treatments that rely on these antibodies less effective than they could be. Understanding exactly how these tumors build their shields is crucial for doctors who want to improve cancer therapies.
A team of researchers at Tel Aviv University has uncovered a hidden layer of this defense system, focusing on a specific protein inside the cancer cell called TRAP1. While scientists already knew that TRAP1 acts as a guardian for the cell's power plants, known as mitochondria, protecting them from stress and damage, its role in fighting off the immune system's artillery was a mystery. The researchers set out to see if this internal guardian was also helping the cell resist the external attack. They worked with several types of human cancer cells, including leukemia and breast cancer, using a mix of genetic tricks and chemical inhibitors to either remove TRAP1 from the cells or force the cells to make too much of it.
The results revealed that TRAP1 is a double agent, working on two fronts to keep the cancer cell alive. First, the researchers found that when TRAP1 is present, it helps the cell recruit a natural regulator called Factor H to its surface. This regulator acts like a stop sign for the immune system's artillery, preventing the formation of the deadly holes that kill the cell. When the researchers removed TRAP1, the cancer cells lost this ability to recruit the stop sign, and the immune system's artillery fired much more effectively, killing the cells. But the story did not end there. The team discovered that TRAP1 also interacts directly with the final piece of the immune weapon, a protein called C9, which is responsible for forming the actual hole in the cell wall. TRAP1 binds to this protein and stops it from assembling, effectively jamming the weapon before it can fire.
Perhaps the most surprising discovery was that TRAP1 does not stay hidden inside the cell during an attack. When the immune system began its assault, the researchers observed TRAP1 rapidly moving out of the mitochondria and appearing on the outer surface of the cell, and even leaking into the space surrounding the cell. Once outside, this protein continued to work, helping to block the immune weapon. When the scientists used antibodies to neutralize this external TRAP1, the cancer cells became much more vulnerable to being killed. Conversely, adding extra TRAP1 to the outside of the cells made them harder to kill. This showed that the protein is not just a passive bystander but an active defender that operates both inside and outside the cell.
The study also looked at what happens inside the cell when the immune attack succeeds. Even when the immune system manages to punch a hole in the cell wall, the cell's power plants, the mitochondria, are among the first things to suffer damage. This damage leads to a surge of harmful molecules that can destroy the cell from the inside. The researchers found that TRAP1 helps the mitochondria withstand this internal chaos. When TRAP1 was missing, the mitochondria failed much faster, and the cells died more quickly. By protecting the power plants, TRAP1 gives the cell a better chance to repair the damage and survive the attack.
These findings suggest that TRAP1 is a central hub for cancer cell resistance, coordinating a defense that spans from the cell's surface to its deepest internal structures. It regulates how the immune system's weapons are blocked on the outside and how the cell survives the damage on the inside. For researchers developing new cancer treatments, this points to a promising strategy: using drugs that block TRAP1 could strip the cancer cell of its dual-layered shield. Such a treatment would not only make the immune system's attack more effective but also prevent the cell from recovering from the damage, potentially making antibody-based therapies work much better against stubborn tumors.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.